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Abstract To evaluate the efficacy and safety of early
steroid withdrawal or steroid avoidance in the tacrolimus
(Tac)-based immunosuppressive regimen for liver trans-
plant recipients. According to the requirements of the
Cochrane systematic review, a thorough literature search
was performed in the PubMed/MEDLINE and Cochrane
electronic databases between 1995 and 2011 using the key
words ‘‘liver transplantation,’’ ‘‘Tac,’’ and ‘‘steroid free’’ or
‘‘steroid withdrawal,’’ restricting articles to the English
language. Data were processed for a meta-analysis by Stata
12 software. Altogether 17 prospective randomized con-
trolled trials containing 1,980 transplanted patients were
included in this study. The overall pooled RR estimates of
1-, 2-, 3-, and 5-year patient and graft survival rates were
0.985, 0.998, 0.995, and 1.100 (95 % CI 0.925–1.048,
0.934–1.067, 0.894–1.107, and 0.968–1.250, respectively),
as well as 0.998, 0.993, 0.945, and 1.053, respectively
(95 % CI 0.928–1.072, 0.902–1.092, 0.833–1.072, and
0.849–1.307, respectively). The other pooled RR estimates
of acute rejection and chronic rejection rates for all
enrolled studies were 1.077 and 0.311 (95 % CI
0.864–1.343 and 0.003–37.207). As for secondary predic-
tors, the pooled RR estimates such as HCV recurrence,
HCC recurrence, diabetes, hypertension, kidney dysfunc-
tion, bacterial infection, and CMV were 1.101, 1.403,
1.836, 1.607, 0.842, 1.096, and 2.280, respectively (95 %
CI 0.964–1.257, 0.422–4.688, 1.294–2.606, 0.926–1.228,
0.693–1.022, 0.783–1.533, and 1.500–3.465, respectively).
There were no differences between the steroid group and
steroid-free group for all clinical observational indices
except for the incidence of diabetes (p = 0.001) and CMV
infection (p \ 0.001). In summary, our study indicate that
rapid discontinuation of steroid in the Tac-based immu-
nosuppressive regimen may not lead to an increased risk of
morbidity and rejection rate.
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Orthotopic liver transplantation (OLT) has been recognized
as a well-established therapeutic option for a subset of
patients with benign end-stage liver diseases as well as
early stage hepatocellular carcinoma (HCC), achieving a
favorable long-term survival rate in many liver transplant
centers in recent years [1]. It must be admitted that the
success of OLT is owed to the pioneers developing the
surgical procedures and to the researchers discovering the
available medications related to allograft rejection pre-
vention [2]. Although liver allograft is generally considered
immunologically privileged, and hyperacute rejection is
rarely observed, the substantial short- and long-term mor-
bidity associated with acute and chronic rejection have still
set off a wave of investigators seeking a safe and effective
immunosuppressive regimen for liver transplant recipients
[3, 4].
Steroids have long been recognized as part of the
immunosuppressive regimen for induction and mainte-
nance since the advent of clinical OLT [5]. Boluses of
high-dose steroids are routinely administered during and
after the operation for the control of acute cellular rejection
in many liver transplant centers. However, prolonged use
of steroids is associated with multiple severe side effects
including hypertension, hyperlipidemia, obesity, diabetes
mellitus, osteoporosis, infectious complications, and par-
ticularly growth retardation in children [6]. In addition,
hepatitis C virus (HCV) and tumor recurrence upon OLT
should also be taken into consideration when patients are
exposed to high-dose long-term steroids [7–10]. In such
circumstances, Pirenne et al. reported the long-term
(median = 40 months) follow-up data of a prospective
study designed to determine whether OLT could be per-
formed with no steroids at all. This prospective single-
center pilot study showed that OLT without steroids is
feasible and yields no penalty in terms of acute and chronic
rejection, immune graft loss, graft function, patient and
graft survival [11]. An experience from Germany with
about 30 adult liver graft recipients subjected to dual
maintenance immunosuppression consisting of tacrolimus
(Tac) and mycophenolate mofetil (MMF) without pro-
phylactic steroids revealed that patient and graft survival at
2 years was 86.7 and 83.9 %, respectively [12]. All
rejections were completely reversible by temporary addi-
tion of steroids. Therefore, the authors speculated that
double drug immunosuppression with Tac and MMF is
effective and safe in terms of patient and graft survival as
well as incidence and severity of rejection [12]. In addition,
close drug monitoring is advised after OLT in order to
avoid under- or over-immunosuppression, which may be
caused by impaired absorption or metabolism [12]. Thus,
minimization of steroid usage including steroid-sparing or
steroid-free immunosuppressive regimens seems to be the
pursued goal for all liver transplant experts to achieve
better outcomes [13–16].
However, several pilot studies and a few randomized
trials have explored this possibility with mixed results.
Reggiani et al. [17] performed a single-center, randomized,
1:1, open-label, controlled study and speculated that a
primary immunosuppressive regimen based on Tac and
low-dose MMF without steroids is safe but unable to pre-
vent acute rejection at 1 week after transplantation even if
early acute rejection does not affect the outcome in terms
of morbidity and graft or patient survival. Foroncewicz
et al. [18] in Poland conducted a 6-year, single-center,
retrospective study including 25 liver transplant recipients.
Though results indicated that a steroid-free regimen of Tac
is as effective as Tac/steroid in achieving good patient and
graft survival, no substantial benefits concerning the safety
of Tac therapy were evident during long-term follow-up
[18].
More recently, considering the potential detrimental
effect on renal functions resulting from the usage of high-
dose Tac instead of steroid, some induction agents for
specific immunological tolerance including polyclonal
rabbit antithymocyte globulin (RATG) and IL-2 receptor
monoclonal antibody (basiliximab or daclizumab) have
been suggested in triple or quadruple immunosuppressive
protocols during OLT, which could minimize the use of
Tac and limit renal toxicity [19–21]. To date, there is no
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consensus about the role of steroid minimization in the
Tac-based immunosuppressive regimen for liver transplant
recipients. The purpose of our study was to conduct a
systematic review and meta-analysis of the published
prospective randomized controlled trials since 1995 con-
cerning the efficacy and safety of steroid elimination in a
Tac-based immunosuppressive regimen for OLT patients.
Methods
This is a systematic review including a meta-analysis,
which was performed according to the preferred reporting
items for the systematic reviews and meta-analyses
(PRISMA) statement [22] and the Cochrane Handbook for
Systematic Reviews of Interventions [23].
Search strategy and selection criteria
Two authors (Jinyang Gu and Jun Li) independently sear-
ched the databases PubMed/MEDLINE and Cochrane
Central Register for all levels of evidence from medical
research articles published in print or electronically in
English from 1995 to 2011. A global literature search was
undertaken by combinations of the following search terms:
‘‘liver transplantation,’’ ‘‘Tac,’’ and ‘‘steroid free’’ or
‘‘steroid withdrawal’’ for the purpose of the role of steroid
minimization in the Tac-based immunosuppressive regi-
men for liver transplant recipients.
The detailed inclusion criteria of trials were as follows:
(1) to assure the quality of analysis, only randomized
controlled trials were included in the study; (2) compari-
sons of outcomes were made between a Tac-based immu-
nosuppressive regimen with (lasting time more than
3 months) or without steroid (lasting time within 3 months)
for OLT; (3) if multiple publications reported estimates
based on the same study population, the largest or most
recent sample was used; (4) studies must have reported
patient or graft survival rates, acute or chronic rejection
prevalence, as well as complication incidence in relation to
steroid usage; and (5) our search included only those ori-
ginal articles published in English.
Data extraction and outcome measures
Two investigators (Jinyang Gu and Jun Li) independently
determined the eligibility of each publication for the sys-
tematic review and meta-analysis by filling in a Microsoft
Excel spreadsheet and evaluating study quality, with dis-
agreements resolved by a third reviewer (Jun Wang).
Extracted data included general information (first author,
year of publication, study center, and sample size),
demographics of participants (gender ratio, mean age,
concomitant disease, and MELD score), characteristics of
clinical interventions (etiology distribution and immuno-
suppressive regimen), primary endpoints (survival rates
and rejection rates), and secondary endpoints (complication
incidences related to steroid usage) from the texts, tables,
and graphs of published eligible trial reports. Pooled out-
come measures for OLT in a Tac-based immunosuppres-
sive regimen with or without steroid involved patient and
graft survival rates at 1, 3, and 5 years, incidence of acute
and chronic rejection, incidence of recurrent hepatitis C or
HCC, rates of infectious complications, post-OLT meta-
bolic disease occurrence, as well as kidney dysfunction.
Fig. 1 Diagram of the literature search and selection process. A total
of 252 citations comprising 151 publications in PubMed and 101 in
the Cochrane Central Register were yielded between 1995 and 2011.
We identified 55 potentially relevant studies that were retrieved and
reviewed by titles and abstracts, 25 of which were further excluded
because of the absence of a control group or lack of a detailed
outcome index. Of the 30 possible studies meeting our inclusion
criteria, 13 duplicate papers deriving from the same clinical centers
were excluded, and finally 17 eligible full-text articles were included
with the largest population and distinct observational index in this
meta-analysis, which were further divided into two sections consist-
ing of studies with comparison of Tac-based immunosuppressive
regimens with steroids or not, as well as with induction agents or not
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Quality assessment
Two authors (Jinyang Gu and Jun Wang) independently
assessed the methodological quality of the included trials
using the quality checklist recommended by the Cochrane
Handbook [24]. The following domains on the risk of bias
were assessed: randomization, patients blinded, conceal-
ment of treatment allocation, intention-to-treat analysis,
and incomplete outcome. We resolved all disagreements by
discussion and referral to a third author (Jun Li) for
adjudication.
Data synthesis and analysis
We processed data in accordance with the Cochrane
Handbook for Systematic Reviews of Interventions [23].
Funnel plots and Egger’s tests were created using standard
techniques for detecting publication bias. For randomized
controlled trials, outcome data were pooled using a random
effect model weighted by the inverse variance. The meta-
analyses results of continuous variables were expressed as
mean differences and as risk ratios (RR) for binary out-
comes with 95 % CI. Meta-analyses of the binary variables
were conducted on the log-odds ratios to satisfy the
assumption of normality of effect sizes. Statistical analyses
were performed using STATA 12. Instead, we undertook
specific stratified meta-analyses to examine the sensitivity
of the findings of the review to key potential causes of
heterogeneity.
Publication bias
We assessed the potential for publication bias through
visual inspection of funnel plot asymmetry and evaluated
the statistical significance of differences among the
including trials with Begg’s test.
Results
Literature search results
The electronic database searches yielded a total of 252
citations comprising 151 publications in PubMed and 101
in the Cochrane Central Register between 1995 and 2011.
We identified 55 potentially relevant studies that were
retrieved and reviewed by titles and abstracts, 25 of which
were further excluded because of the absence of a control
group or lack of a detailed outcome index. Of the 30
possible studies meeting our inclusion criteria, 13 duplicate
papers derived from the same clinical centers were exclu-
ded from our present study, and we finally included 17
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distinct observational index in this meta-analysis, which
were further divided into two sections consisting of studies
with comparison of Tac-based immunosuppressive regi-
mens with steroids or not, as well as with induction agents
or not. The flow chart of the search and selection is illus-
trated in Fig. 1.
Characteristics of included studies
Study and patient characteristics are summarized in
Tables 1 and 2. Overall, the 17 randomized, controlled
trials enrolled a total of 1,980 participants with a mean age
of 44.4 years, of which approximately 65 % were male.
Five studies were based in the USA [26, 32, 35, 36, 38],
three in Germany [25, 28, 31], three in Italy [17, 29, 34],
and one each in Spain [27], China [9], UK [30], France
[33], Belgium [37], and Poland [18]. The 17 prospective
randomized controlled studies enrolled patients with dis-
tinct primary diseases eligible for OLT such as hepatitis B
virus (HBV) [18, 27, 31–33], HCV infection [18, 25–27,
30–33, 35, 36, 38], HCC [9, 17, 26, 27, 30, 31, 33, 37],
primary sclerosing cholangitis (PSC) or primary biliary
cirrhosis (PBC) [17, 18, 31, 32], alcoholic cirrhosis [17, 18,
26, 27, 31], and autoimmune hepatitis (AIH) [28, 32]. A
proportion of selected studies (6/17) described concomitant
diseases such as diabetes [27, 29–31, 33], hypertension [27,
31], cytomegalovirus (CMV) infection [33, 34], Epstein-
Barr virus (EBV) infection [33, 34], and metabolic disease
[31, 33, 34, 37]. Of these 17 studies, all but 2 publications
[28, 30] reported intraoperative steroid usage to avoid
hyperacute rejection. As far as postoperative steroid dura-
tion was concerned, it was totally different among liver
transplantation centers ranging from 3 to 72 months for the
control group (steroid group) and \3 months for the
experimental group (steroid-free group). The remnant
observational index including time of Tac and MMF
duration, and Tac blood level is displayed in detail in
Table 2. The overall 17 prospective randomized controlled
trials were then divided into two parts in terms of whether
steroid was employed upon OLT or not (Sect. I), as well as
whether induction agents were employed during OLT
(Sect. II), which was further analyzed for all 17 trials and
for each section, respectively. Tables 3 and 4 display a
summary of outcomes including survival rates and com-
plication incidence.
Quality assessment
We evaluated the quality of each trial according to the
Jadad scale. Five domains were assessed: randomization,
patient blinding, concealment of treatment allocation,
intention-to-treat analysis, and incomplete outcome (Sup-
plementary Table 1). All included articles described their
study design as prospective randomized controlled trials.
Only 11.8 % (2/17) reported patient blinding and con-
cealed allocation [30, 31], and 23.5 % (4/17) used inten-
tion-to-treat analysis [26, 30, 33, 38]. In addition, the
overwhelming majority of publications lacked complete
outcome data except for two [27, 31].
Primary predictors
Supplementary Table 2 summarizes the meta-analysis
results of pooled primary outcomes for all 17 enrolled
RCTs in this study. The overall 1-, 2-, 3-, and 5-year
pooled RR estimates of patient survival rates and graft
survival rates were 0.985 (95 % CI 0.925–1.048), 0.998
(95 % CI 0.934–1.067), 0.995 (95 % CI 0.894–1.107),
1.100 (95 % CI 0.968–1.250), as well as 0.998 (95 % CI
0.928–1.072), 0.993 (95 % CI 0.902–1.092), 0.945 (95 %
CI 0.833–1.072), and 1.053 (95 % CI 0.849–1.307),
respectively (Fig. 2a, b). The other pooled RR estimates of
acute rejection and chronic rejection rates for all enrolled
studies were 1.077 (95 % CI 0.864–1.343) and 0.311
(95 % CI 0.003–37.207) (Fig. 2c). There were no differ-
ences between the steroid group and steroid-free group for
the primary endpoints.
The detailed pooled RR estimates of survival rates and
rejection rates for Sects. I and II are listed in Supplemen-
tary Tables 3 and 4, respectively. In Sect. I, the overall 1-,
2-, 3-, and 5-year pooled RR estimates of patient survivals
and graft survival rates were 0.988 (95 % CI 0.896–1.090),
1.032 (95 % CI 0.931–1.145), 1.021 (95 % CI
0.876–1.189), and 1.100 (95 % CI 0.968–1.250), as well as
0.991 (95 % CI 0.879–1.118), 1.013 (95 % CI
0.847–1.212), 0.905 (95 % CI 0.606–1.352), and 1.061
(95 % CI 0.855–1.316), respectively (Fig. 3a, b). The other
pooled RR estimates of acute rejection and chronic rejec-
tion rates were 0.983 (95 % CI 0.774–1.247) and 0.126
(95 % CI 0.030–0.526) (Fig. 3c). In Sect. II, the overall 1-
and 2-year pooled RR estimates of patient survival rates
and graft survival rates were 0.982 (95 % CI 0.904–1.065)
and 0.977 (95 % CI 0.895–1.067) as well as 1.005 (95 %
CI 0.916–1.102) and 0.968 (95 % CI 0.863–1.085),
respectively (Fig. 4a, b). The pooled RR estimate of acute
rejection rates was 1.130 (95 % CI 0.927–1.377) (Fig. 4c).
In general, steroid elimination and plus induction agent
employment during OLT could achieve comparably
favorable survival rates and rejection rates of no signifi-
cance compared with traditional long-term steroid usage.
Secondary predictors
As shown in Supplementary Table 2 and Fig. 2d, the
pooled RR estimates of secondary outcomes such as HCV
recurrence (1.101; 95 % CI 0.964–1.257), HCC recurrence
206 Hepatol Int (2014) 8:198–215
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Fig. 2 Forest plot of RR and 95 % CI for patient survival rates (a), graft
survival rates (b), and rejection rates (c) and incidence of complications
(d) for all 17 enrolled RCTs in this study. The horizontal lines represent the
95 % CI of the RR for the steroid group compared to steroid-free group in
each study. The black box in the middle of the CI represents the single best
estimate of RR in that study. The width of the CI is related to the power of the
study and inversely associated with sample size. In addition, the pooled or
combined RR results of the meta-analysis are represented by a diamond, the
width of which is the CI for the pooled data. The vertical line is typically
displayed to indicate no effect when RR = 1. When the CI crosses the
vertical line of no effect, we must accept the null hypothesis of no difference
between two groups. Only if the CI remains clear of the vertical line of no
effect can we reject the null hypothesis and conclude that steroid
minimization likely caused the outcome. We used a fixed effect model for
meta-analysis, except that heterogeneity between studies was considered
present if the p value was\0.1 or I2 was more than 50 %, where we used a
random effect model instead
Hepatol Int (2014) 8:198–215 207
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(1.403; 95 % CI 0.422–4.688), diabetes (1.836; 95 % CI
1.294–2.606), hypertension (1.607; 95 % CI 0.926–1.228),
kidney dysfunction (0.842; 95 % CI 0.693–1.022), bacte-
rial infection (1.096; 95 % CI 0.783–1.533), and CMV
(2.280; 95 % CI 1.500–3.465) for all 17 RCTs were
presented. Of note, the combined complication incidence
estimates including diabetes (p = 0.001) and CMV
(p \ 0.001) were significantly reduced with early steroid
withdrawal. In Sect. I, the pooled RR estimates of HCV
recurrence (0.926; 95 % CI 0.586–1.463), HCC recurrence
Fig. 2 continued
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Fig. 3 Forest plot of RR and 95 % CI for patient survival rates (a), graft
survival rates (b), and rejection rates (c) and incidence of complications
(d) for Sect. I in this study. The horizontal lines represent the 95 % CI of
the RR for the steroid group compared to the steroid-free group in each
study. The black box in the middle of the CI represents the single best
estimate of RR in that study. The width of the CI is related to the power
of the study and inversely associated with sample size. In addition, the
pooled or combined RR results of the meta-analysis are represented by a
diamond, the width of which is the CI for the pooled data. The vertical
line is typically displayed to indicate no effect when RR = 1. When the
CI crosses the vertical line of no effect, we must accept the null
hypothesis of no difference between two groups. Only if the CI remains
clear of the vertical line of no effect can we reject the null hypothesis
and conclude that steroid minimization likely caused the outcome. We
used a fixed effect model for meta-analysis, except that heterogeneity
between studies was considered present if the p value was\0.1 or I2 was
more than 50 %, where we used a random effect model instead
Hepatol Int (2014) 8:198–215 209
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(2.437; 95 % CI 0.890–6.678), diabetes (1.223; 95 % CI
0.766–1.954), hypertension (0.975; 95 % CI 0.503–1.889),
kidney dysfunction (0.807; 95 % CI 0.442–1.472), bacte-
rial infection (0.529; 95 % CI 0.261–1.072), and CMV
(2.137; 95 % CI 0.809–5.643) are displayed in Fig. 3d. No
significance was observed between the steroid group and
steroid-free group with respect to any complication inci-
dence. In Sect. II, the pooled RR estimates of HCV
recurrence (1.136; 95 % CI 0.993–1.300), diabetes (1.170;
95 % CI 1.093–1.252), hypertension (1.036; 95 % CI
Fig. 3 continued
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0.980–1.095), kidney dysfunction (0.934; 95 % CI
0.869–1.004), bacterial infection (1.204; 95 % CI
0.941–1.541), and CMV (1.079; 95 % CI 0.968–1.203) are
displayed in Fig. 4d. Compared with the non-induction
group, the combined diabetes incidence estimates of the
induction group were significantly decreased upon induc-
tion agent intervention (p \ 0.001). The detailed pooled
RR estimates of complication incidence for Sects. I and II
are listed in Supplementary Tables 3 and 4, respectively.
Publication bias
The funnel plot did not show any asymmetrical pattern, and
the Begg’s test did not reveal any significant publication
bias (data not shown).
Discussion
To the best of our knowledge, our current study represents
the first evidence-based medicine article concerning the
efficacy and safety of steroid minimization in the Tac-
based immunosuppressive regimen for liver transplant
recipients. In this meta-analysis, altogether 17 clinical trials
containing 1,980 transplanted patients published between
1995 and 2011 were finally enrolled in this study. To
clarify whether induction agents could reduce potential
adverse effects related to steroid avoidance by modulating
the immunologic status, the enrolled studies were divided
into two sections in terms of: (1) whether a steroid was
employed upon OLT or not; (2) whether induction agents
were employed during OLT or not. To our excitement, our
results indicated that early steroid withdrawal or steroid
avoidance in the Tac-based immunosuppressive regimen is
safe and effective for the prevention of acute and chronic
rejection after OLT with the benefit of a decrease in the
incidence of diabetes and CMV infection. Although the
underlying data remain to be systematically investigated,
the present study revealed the introduction of some
induction agents including RATG, basiliximab and dac-
lizumab in triple and quadruple immunosuppressive pro-
tocols are likely more effective in lowering the high-dose
usage of Tac in order to minimize the potential detrimental
effect on renal functions. In the following paragraphs,
some important issues pertaining to steroid elimination in
the Tac-based immunosuppressive regimen for liver
transplant recipients will be discussed.
Since the discovery of cortisol in 1937, steroids have
paved the way for successful medical immunosuppression,
especially for later organ transplantation, and proved the
reversibility of rejection. However, in the modern era of an
improved immunosuppressive protocol, it is necessary to
critically assess the risk:benefit ratio of long-term steroid
therapy during and after liver transplantation. To date,
several studies have shown that weaning from steroids can
be successfully carried out shortly after liver transplanta-
tion, thereby decreasing typical steroid-related side effects
including new-onset diabetes mellitus, lipid metabolism
abnormality, viral hepatitis recurrence and liver malig-
nancy relapse [27, 29, 30, 35, 38]. In spite of these
encouraging results, the theoretical advantages should be
carefully balanced against the potential risks of increasing
nonsteroidal immunosuppressive complications and a
higher incidence of rejection. Jain et al. [39] reported
23.8 % of patients under the Tac-based immunosuppres-
sive regimen required steroid reintroduction for late
rejection, recurrence of the autoimmune process, renal
impairment, or the concomitant presence of other medical
conditions. Thus, the authors concluded that long-term
sustained freedom from steroids may not be possible in all
patients under Tac secondary to these conditions. Another
multicenter, 1-year, comparative, double-blind, placebo-
controlled study evaluating the efficacy and safety of an
immunosuppressive regimen with steroid withdrawal at
day 14 revealed a higher incidence of acute rejection, only
balanced by a trend of a lower need for antidiabetic
treatment [40]. The previous study suggested that steroid
withdrawal or avoidance may not always be safe and
needed. Steroid reintroduction may be necessary for late
rejection episodes, recurrent autoimmune disease, or renal
impairment due to Tac. As mentioned above, there are
three categories of individuals in whom the long-term
adverse effects of steroids after liver transplantation are
particularly detrimental. First, most steroid-induced side
effects occurred in children, like what was encountered in
adults. Of note, growth retardation and Cushingoid features
are of concern in the pediatric transplant recipients. Sec-
ond, those patients with cardiovascular risk factors of
hyperlipidemia, hypertension, or diabetes certainly have a
contraindication to long-term steroid therapy. Last but not
least, it could be supposed that rapid steroid tapering or
being steroid free will serve as one of the most important
determinants for slowing down the progression to tumor
relapse.
For years corticosteroid induction has been the tradi-
tional standard immunosuppressive modality for OLT.
Recently, induction therapy with antibodies has been
increasingly used without widespread acceptance. The
underlying mechanism of induction therapy is to inhibit
thymus-derived lymphocyte activation through T cell pool
depletion with either monoclonal antibodies or polyclonal
antibodies (RATG), or to block specific IL-2 receptors
(basiliximab or daclizumab), which may lead to reduction
of the incidence of acute rejection and act as steroid-
sparing minimization alternatives [19]. Mangus et al. [20]
retrospectively analyzed data obtained from a single-center
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Fig. 4 Forest plot of RR and 95 % CI for patient survival rates (a), graft
survival rates (b), and rejection rates (c) and incidence of complications
(d) for Sect. II in this study. The horizontal lines represent the 95 % CI
of the RR for the non-induction group compared to the induction group
in each study. The black box in the middle of the CI represents the single
best estimate of RR in that study. The width of the CI is related to the
power of the study and inversely associated with sample size. In
addition, the pooled or combined RR results of the meta-analysis are
represented by a diamond, the width of which is the CI for the pooled
data. The vertical line is typically displayed to indicate no effect when
RR = 1. When the CI crosses the vertical line of no effect, we must
accept the null hypothesis of no difference between two groups. Only if
the CI remains clear of the vertical line of no effect can we reject the null
hypothesis and conclude that the prescription of induction agents during
steroid minimization likely caused the outcome. We used a fixed effect
model for meta-analysis, except that heterogeneity between studies was
considered present if the p value was\0.1 or I2 was more than 50 %,
where we used a random effect model instead
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research database ranging from 2001 to 2008 comparing
transplant outcomes and complications. The authors con-
cluded that RATG-based induction immunosuppression
could be safely used in adult OLT recipients with excellent
survival, low rejection rates, and a comparably acceptable
incidence of side effects [20]. Experts from the University
of Tokyo in Japan conducted an observational study to
evaluate the efficacy and safety of basiliximab as rescue
therapy for the treatment of acute cellular rejection [41]. In
contrast to 11 patients who received steroid therapy for
acute cellular rejection, there were no significant immedi-
ate adverse effects in the basiliximab group which under-
went liver transplantation for HCV cirrhosis [41]. In
addition, recent studies have shown that immunosuppres-
sion with low-dose daclizumab and delayed initiation of
Tac had significant benefits in preserving renal function
after OLT [42]. However, the application of the induction
therapy with biologic agents carrying elevated risks of
over-immunosuppression, CMV viremia, posttransplant
lymphoproliferative disease, as well as HCV recurrence is
still controversial [43]. In our present study, we have
demonstrated comparable patient and graft survival with
significantly lower rates of HCV recurrence, diabetes,
bacterial infection, and CMV infection as compared to no
induction intervention.
Conclusions
In conclusion, the present investigation systematically
reviewed the recent 17 prospective randomized controlled
clinical trials concerning the application of steroid mini-
mization in the Tac-based immunosuppressive regimen for
liver transplant recipients, and a meta-analysis was per-
formed to reveal the efficacy and safety of early steroid
withdrawal or complete avoidance. Furthermore, adverse
events potentially related to steroids were less frequently
observed with the use of antibody agents for induction
therapy while low-dose Tac could be maintained.
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